Treatment of aromatase inhibitor-resistant
disease
Aromatase
inhibitors are
first-line
endocrine
therapy for
postmenopausal
patients
“Optimal post-
aromatase
inhibitor
treatment is
uncertain”
Approximately
50% of ER+
patients do NOT
respond to initial
treatment
Even those who do
respond to initial
treatment will
eventually
progress
ER+, estrogen receptor positive
Normanno N, et al.
Endocr Rel Cancer.
2005;12:721-747; National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology: Breast
Cancer. V.2012. NICE, CG81 Advanced breast cancer: Diagnosis and treatment. 2009 Available at
Cardoso F, et al.
Ann Oncol.
2010;21(suppl 5): v15-v19 ; Cardoso F, et al.
Breast.
2012;24:242-252.
AFI12-C091a October 2012
